Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5538)	1/24/2002 6:28:39 PM
From: scott_jiminez	Read Replies (1) \| Respond to of 52153

<<And they unbelievably hyped their stock (up to nearly $50 if I recall) in early 2000, even though they were many years away from any practical application of their technology.>> Hyped the stock??? Cut me a break Peter. You know as well as anyone that the absurd valuations in 2000 was the result of a biotech bubble as bloated as any other sector, internet inclusive. Thus your claim that the reason ARIA zoomed up because of company-specific hyping is patently ridiculous. Look at the charts of the vast majority of BTs during the period you cite: you will find that countless BTs (many hyped unabashedly on SI) display an IDENTICAL chart pattern to that of ARIA. But, in the end, your point is valid, but in a much more general sense: the entire BT sector 'unbelievably hyped their stocks' in 1999 and 2000', most up 5 to 10 fold (!), even though the vast, VAST majority of companies 'were many years away from any practical application of their [drugs or] technology'. I would readily and rapidly accept that ARIA was one small part, one of many similar cases, of the incredibly hyped-up biotech bubble of early 2000.